Gepotidacin: A New Mechanism to Combat Resistant Urinary Tract Infections
Tracking # 20-1390574
Course overview
Antimicrobial resistance continues to outpace antibiotic development, underscoring the need for agents with novel mechanisms. Gepotidacin, approved by the U.S. Food and Drug Administration in 2025, is a first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV at binding sites distinct from those targeted by fluoroquinolones, providing activity against resistant uropathogens. Approved for uncomplicated urinary tract infections (uUTIs) in female patients aged 12 years and older, gepotidacin has demonstrated non-inferior efficacy to nitrofurantoin in the phase 3 EAGLE-2 and EAGLE-3 trials while maintaining activity against fluoroquinolone-resistant E. coli. This course reviews gepotidacin's mechanism, pharmacology, clinical trial evidence, dosing, safety profile, and role in antimicrobial stewardship for the management of resistant uUTIs.
Subject areas
This course counts toward the state boards and subject areas below.